43 results about "Adiponectin" patented technology

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

This invention discloses a method and sensor for adiponectin detection using a polyaniline and polyacrylic acid-modified wire mesh carbon electrode, relating to the field of adiponectin detection technology. The method involves electrochemically activating the wire mesh carbon electrode, electropolymerizing it to form a polyaniline-polyacrylic acid composite modification layer, immobilizing adiponectin monoclonal antibody after activation with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, blocking the antibody with bovine serum albumin, and reacting it with a serum sample. The adiponectin concentration is determined based on the peak potential shift and peak current change. This invention simultaneously achieves both conductive transport and antibody immobilization, reduces non-specific adsorption and serum interference, and improves detection sensitivity, repeatability, and quantitative accuracy.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention belongs to the technical field of electrochemical analysis and detection, and particularly relates to an electrochemical immunosensor for detecting adiponectin as well as a preparation method and application of the electrochemical immunosensor. The preparation method comprises the following steps: (1) connecting a screen-printed electrode SPCE to an electrochemical workstation by using a 0.01 M PBS (Phosphate Buffer Solution) with the pH value of 7.4, performing-0.2 V-1. 2V cyclic voltammetry scanning, and activating for 10 circles under 50mV / S; and (2) by taking 0.01-1M H2SO4 as a base solution, connecting the screen-printed electrode SPCE to an electrochemical workstation, carrying out electro-polymerization on poly-o-phenylenediamine in a 50-100mM o-phenylenediamine and NH2-UiO-66 solution to form a poly-o-phenylenediamine and NH2-UiO-66 composite modified electrode, washing with deionized water, and drying at room temperature. (3) soaking the modified electrode in a glutaraldehyde solution for 10-70 minutes, cleaning with deionized water, drying at room temperature, adding 10-100 [mu] L of ADPN antibody solution and 100-600 [mu] g / mL of ADPN antibody solution, and incubating; and (4) washing with ionized water, drying at room temperature, preventing non-specific binding sites at 37 DEG C for 0.5-1.5 hours by using 3-10 microliters of 0.8-1.2 wt% casein solution, and washing the screen-printed electrode again to obtain the electrochemical immunosensor.

The invention discloses a preparation method of an electrochemical immunosensor for detecting adiponectin and a method for quantitatively detecting the adiponectin by adopting the electrochemical immunosensor, provides a new strategy for fixing an adiponectin antibody by a one-step method, and constructs the electrochemical immunosensor based on a gold sputtering silver wire screen printing electrode (Au / AgSPE). The rapid, high-sensitivity and stable detection of the adiponectin is realized, so that the conversion of the adiponectin detection technology to instant detection application is promoted. Only a portable electrochemical workstation is needed in the detection process, and large biochemical analysis equipment is not needed. And the screen printing electrode and the sputtering technology support large-scale production, and cost reduction and popularization are facilitated.

The present invention includes methods of using improved compositions and improved compositions comprising thermally stable plant juice soluble vegetable proteins for resisting pathogenic effects; the improvements include that the composition comprising heat stable plant juice soluble vegetable proteins is essentially a water insoluble concentrated substance free of components that are more soluble in plant juice, and is enriched in heat stable proteins of plant juice; dosage forms prepared from the composition are useful for adiponectin agonist action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity, and are useful for antimicrobial action for reducing the risk of one or more conditions selected from the group consisting of type II diabetes, hyperlipidemia, atherosclerosis, hypertension, heart disease and obesity. The present invention relates to antimicrobial agents for reducing the risk of or treating microbial infections in plants and animals with or without synergy with other antimicrobial agents. The present invention includes a composition substantially characterized by the infrared absorption spectrum provided in the present invention.

The application discloses a rice anti-Rhizoctonia solani leptin receptor OsPLS3 protein and an encoding protein and application thereof. The rice leptin receptor OsPLS3 protein has an amino acid sequence as shown in SEQ ID NO. 3. A coding gene of the rice leptin receptor gene OsPLS3 has a genomic nucleotide sequence as shown in SEQ ID NO. 1, and an open reading frame nucleotide sequence of the rice leptin receptor gene OsPLS3 is as shown in SEQ ID NO. 2. Experiments prove that overexpression of the rice leptin receptor gene OsPLS3 in the application in rice can improve the resistance of the rice to the Rhizoctonia solani, and the rice is more susceptible to the Rhizoctonia solani after knockout, namely, the OsPLS3 positively regulates the resistance of the rice to the Rhizoctonia solani. The rice leptin receptor gene OsPLS3 has important production value for breeding of the rice resistant to the Rhizoctonia solani.

The invention provides a breast cancer risk assessment method which is suitable for BI-RADS compact type high-risk groups with BMI greater than or equal to 28 and estrogen greater than 50pg / mL, and the method comprises the following steps: S100, injecting a temperature-sensitive nano contrast agent which is matched with fat acoustic impedance at 37 DEG C and has tumor environment impedance mutation at 39-42 DEG C; s200, dynamically adjusting the voltage of the molybdenum target tube according to the BMI and filtering by adopting a 40keV energy spectrum; s300, based on the leptin / adiponectin ratio L, the estrogen E and the focus area A, calculating a risk score according to R = 0.7 L + 0.3 E * (1 + 50A); according to the scheme, through high-risk group limitation, temperature-sensitive contrast enhanced ultrasonic specificity, BMI self-adaptive molybdenum target penetration and a multi-parameter fusion model, the detection precision is remarkably improved, the microfocus detection sensitivity reaches 92.3%, and the specificity reaches 88.7%.

The present application provides a method for producing a Citrus medica L. var. sarcodactylis fermentate with the effect of increasing polyphenol intake and adiponectin content. The method for producing a Citrus medica L. var. sarcodactylis fermentate with the effect of lowering blood lipids comprises the following steps: washing, air-drying, and breaking the cell wall, inoculating and fermenting, comprehensive filtering, sterilizing, and finally forming a Citrus medica L. var. sarcodactylis fermentate that can increase the total polyphenol content in the human body and improve the adiponectin content in the body.

Systems and methods are provided for providing diabetes patient treatment guidance for a patient in which a biochemical data set is obtained. The biochemical data set comprises test results from a single blood draw of the patient including at least three measurements selected from the set: a high-sensitivity c-reactive protein test, an adiponectin level test, an intact proinsulin level test, an insulin level test, a C-peptide test, a HbA1c test, and an eGFR level test. A demographic data set for the patient is also obtained that comprises the patient's gender and diabetes stage. The biochemical data set and demographic data set is run against one or more rules to determine a first patient therapy pattern. Then, a report is prepared based on an identity of the first therapy patient pattern. The report sets priorities among intervention classes for the patient based on the identity of the first patient pattern.

The present application relates to the technical field of in vitro diagnosis, in particular to a chemiluminescence-based adiponectin detection method, which uses MQ silicon resin-coated Fe3O4 magnetic microspheres as a solid-phase carrier, captures adiponectin in a sample through a double-antibody sandwich immunoreaction, and uses HRP enzyme-labeled detection antibodies to combine with a luminol-phenolic enhanced chemiluminescence system for signal detection. The key lies in significantly reducing non-specific background by optimizing washing conditions and substrate formula, and regulating luminescence kinetics to adapt to the reading window of mainstream chemiluminescence instruments. The present application uses HRP enzyme-catalyzed cascade amplification and an optimized luminol enhancement system, and the detection lower limit is better than that of conventional methods, meeting the needs of early metabolic risk screening for ultra-low concentration detection, the linear detection range covers 0.01 mg / L to 100 mg / L, effectively avoiding the common hook effect in high-concentration samples, and the signal-to-noise ratio is greatly improved, ensuring the reliability of low-value sample detection.

A method for determining the amount of adiponectin in a sample by mass spectrometry includes: (a) subjecting adiponectin from the sample to an ionization source under conditions suitable for generating one or more adiponectin ions detectable by mass spectrometry; (b) determining the amount of one or more adiponectin ions by mass spectrometry; and (c) determining the amount of adiponectin in the sample from the amount of one or more adiponectin ions determined in step (b).

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The present invention relates to a novel peptide derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptide derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.

The application discloses a method for up-regulating adiponectin of perivascular adipose tissue, and belongs to the technical field of molecular biology. The method is targeted at cells of perivascular adipose tissue, increases mRNA and protein expression of LRP1 of adipocytes, activates an autophagy-related pathway, and reduces expression of proinflammatory factors.

The invention relates to the field of stem cell culture, in particular to adiponectin gene modified mesenchymal stem cells as well as a preparation method, a medicine and application thereof. The adiponectin gene modified mesenchymal stem cell provided by the invention can overexpress adiponectin to stimulate islet cells, regulate sugar stimulation response and improve insulin secretion amount. The preparation method of the adiponectin gene modified mesenchymal stem cell provided by the invention is simple, and the prepared adiponectin gene modified mesenchymal stem cell is higher in insulin secretion amount and longer in action time in an INS-1 cell sugar stimulation experiment.

The invention relates to an adiponectin receptor regulating peptide as well as a composition, a product and application thereof. The amino acid sequence of the adiponectin receptor regulating peptide is as follows: (a), any one of the amino acid sequences as shown in SEQ ID NO. 1 to 30, SEQ ID NO. 32, SEQ ID NO. 35 to 39, SEQ ID NO. 42, SEQ ID NO. 46, SEQ ID NO. 47, SEQ ID NO. 49 and SEQ ID NO. 50; or (b) any one of amino acid sequences which are obtained by modifying the N end and / or the C end of the adiponectin receptor regulating peptide limited by (a) and have the same or similar functions. The adiponectin receptor regulating peptide provided by the invention can activate an adiponectin receptor / AMPK signal channel and promote hair growth, has multiple effects of oxidation resistance, inflammation resistance and apoptosis resistance, can improve skin aging, and has wide application prospects in the fields of medicines, foods and cosmetics.

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

Disclosed are methods for managing a treatment in an adult individual having systemic lupus erythematosus (SLE) undergoing therapy for lupus nephritis. In aspects, the method comprises detecting a level of each of neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and ceruloplasmin in a urine sample obtained from the individual, the levels of which are used to determine a score at a first time point and a second time point. Whether the individual is responding to the therapy, in particular an induction phase of a therapy, is determined based on a comparison of the first and second score. The therapy may then be continued or adjusted based on that determination.

The present invention relates to a novel peptoid derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptoid derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.

This invention relates to the field of biodetection technology, disclosing a preservation solution, an adiponectin detection kit, its preparation method, and its application. The preservation solution comprises Tris, trehalose, Tween 20, sodium caseinate, PVP-10, Proclin-300, TX-100, surfactant S13, and glycine. This specific formulation effectively prevents quantum dot aggregation and maintains protein activity for a long time. The adiponectin detection kit is based on quantum dot immunofluorescence chromatography technology and includes components such as a sample pad, a release pad, and a nitrocellulose membrane. The release pad is simultaneously coated with quantum dot-labeled antibodies and unlabeled detection line antibodies, and the quantum dot-labeled antibodies are coupled in a cascade manner of "quantum dot-streptavidin-biotinylated antibody". This invention, through liquid dialysis linking technology and a unique release pad antibody premixing process, utilizes the signal amplification effect of the biotin system and the principle of homogeneous reaction, significantly improving the sensitivity, accuracy, and reagent stability of the detection.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte- specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large- adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

The disclosure relates to a substance adiponectin and / or adiponectin receptor agonist (ARA) for use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the subject is preferably receiving checkpoint blockade therapy as a cancer therapy. As well as to a combination medication comprising adiponectin and / or adiponectin receptor agonist (ARA) and a photosensitizing agent for combined use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the treatment further comprises the extracorporeal irradiation of a blood sample of the subject with ultraviolet A (UVA), preferably extracorporeal photopheresis (ECP) therapy.

The invention belongs to the technical field of biomedical cosmetics, and discloses a double-target 5alpha-reductase and adiponectin receptor cyclic peptide as well as application and a preparation method thereof. The cyclic peptide is formed by cyclizing three amino acid units, namely arginine, phenylalanine and tyrosine through peptide bonds, and comprises pharmaceutically acceptable salts, solvates, stereoisomers or isotope labels of the cyclic peptide. The compound reduces generation of dihydrotestosterone by inhibiting 5alpha-reductase, activates an adiponectin receptor AdipoR pathway to promote energy metabolism and proliferation of hair papilla cells, and realizes double-target synergistic anti-alopecia. The invention also discloses application of the cyclopeptide in preparation of medicines or cosmetics for preventing or treating alopecia and a solid-phase synthesis preparation method. Through double-target synergistic interaction, the hair follicle cell proliferation rate can be remarkably increased at extremely low concentration, and the dosage is reduced compared with that of a traditional medicine; the composition is constructed by adopting physiological amino acid, has no systemic sex hormone side effect during local external use, and is high in safety.

This invention provides peptides with anti-obesity and / or anti-diabetic activity, composed of the amino acid sequence of Sequence 1 or Sequence 2. These peptides inhibit fat accumulation, reduce the size of adipocytes, and increase the expression of phosphorylated hormone-sensitive lipase, adenosine monophosphate-activated protein kinase-α1, and comparative gene recognition-58 (CGM-58), which are lipolysis factors, thereby breaking down accumulated fat. This not only exhibits excellent anti-obesity effects but also effectively reduces blood glucose levels, increasing the expression of adiponectin and adenosine monophosphate-activated protein kinase (CGM-58), which improve insulin resistance; increasing the expression of glucose transporter protein 4 (a glucose transport channel); and increasing the expression of insulin receptor substrate-1 (an insulin receptor signaling protein), thus exhibiting excellent effects against diabetes. The peptides of this invention can be effectively used in the prevention or treatment of obesity and / or diabetes.

The application discloses a preparation method of an electrochemical immunosensor for detecting adiponectin and a method for quantitatively detecting adiponectin by using the electrochemical immunosensor, proposes a new strategy for fixing adiponectin antibodies in one step, constructs an electrochemical immunosensor based on a gold sputtering silver screen-printed electrode (Au / AgSPE), and realizes rapid, high-sensitivity and stable detection of adiponectin, so as to promote the conversion of adiponectin detection technology to instant detection application. The detection process of the application only needs a portable electrochemical workstation, and does not need large biochemical analysis equipment. The screen-printed electrode and the sputtering process support large-scale production, and are favorable for reducing cost and popularization.

The present invention relates to a composition comprising (i) at least one GLP1 receptor (GLP1R) agonist and (ii) at least one engineered extracellular vesicle harboring at least one adiponectin polypeptide exposed at its outer surface. It further relates to the use of said composition as a medicament, and in particular, for treating various diseases.

The objective is to provide a previously unknown adipocyte differentiation inducer. [Solution] A fat cell differentiation inducer containing sesamolinol as an active ingredient.